We are very pleased to be collaborating with Xian Janssen, who shares our goal of helping improve the lives of people living with or at risk of type 2 diabetes. Merck has been making continued efforts to expand its portfolio with the aim of providing more high-quality medicines and better treatment options for millions of diabetic patients in China.
Growth in the period was only The Chinese pharmaceutical industry has been growing at an average annual rate of However, the industry is still small-scale with a scattered geographical layout, duplicated production processes, and outdated manufacturing technology and management structures.
The Chinese pharmaceutical industry also has a low market concentration and weak international trading competitiveness, coupled with a lack of patented domestically-developed pharmaceuticals.
Barnet Siu; Investment conditions in China have improved due to the vast consumer demand for pharmaceuticalsthe lower labor costs and the changes resulting from economic reform.
Most domestic manufacturers in the pharmaceutical industry lack the autonomic intellectual property and financial resources to develop their own brand products. Most manufacturers rely on the repetitive production of low value added bulk pharmaceuticals and imitation drugs. In contrast, the top 10 companies in most developed countries control about half the market.
Most of the Chinese drug-makers fall below the 20th ranking, but 30 of the top 50 companies are local.
|What to Read Next||Metaphor Lists The members of a family tree have been used as metaphors in cultures around the world for some time now. Here are a few examples of family metaphors from English.|
|Janssen Pharmaceutica - Wikipedia||Career in technology and tech-enabled companies; prescient facilitator in the adoption of new technologies to spur growth.|
|Xian-Janssen Pharmaceutical (China) and the Euro – Case study - monstermanfilm.com||History[ edit ] The early roots of what would become Janssen Pharmaceutica date back to|
Foreign enterprises have been closely monitoring the expanding OTC market. The pharmaceutical market in China is dominated by its non-branded generic industry that operates with basic technology and simple production methods.
Domestic companies are mainly government owned and fraught with overproduction and losses. The Chinese government has begun consolidating and upgrading the industry in an effort to compete with foreign corporations.
This will change with the separation of hospital pharmacies from healthcare services and with the growing numbers of retail pharmacy outlets. Retail pharmacy outlets are expected to grow in number once the government finally introduces its system to classify drugs as OTC.
The government is now encouraging development of chain drug stores, but the full effect might not be seen for several years. The price of pharmaceutical products will continue to decrease steadily. The central government has been playing a significant role in pharmaceutical price readjustment.
The government compelled and continually 32 times reduced the price of most of the drugs in last 20 years since The rural pharmaceutical market will shift significantly.
Eli Lilly and Company opened its first overseas representative office in Shanghai in A survey of 16 typical city hospitals, the usage of drugs increased by Biotech -related medical products and medical equipment make up the rest.
ZhejiangGuangdongShanghaiJiangsu and Hebei provinces have always been among the top five most productive provinces in China. Each of these provinces has grown steadily by an average of 20 per cent per annum from to with the exception of Jiangsu in and and reflects an increasingly healthy developing trend in the Chinese pharmaceutical industry.
Most pharmaceutical firms are located in the southeastern zone that includes two well-developed areas and three under-developed areas. The two most popular areas of well-developed pharmaceutical industry, called the growth poles, are the Eastern China zone of which Zhejiang province is located in the centre and the South China zone represented by the Guangdong province.
The total output value of these two provinces accounted for 21 per cent of the total output value of pharmaceutical industry of China in The three sub-developed areas of pharmaceutical industry, called the potential points, are also identified as the Middle China Zone, the Northeastern Zone and the Southwestern Zone, centralised in Hebei Province, Heilongjiang province and Sichuan province, respectively.
The development of the pharmaceutical industry in China was found to be predominantly driven by economic factors.Ketoconazole. In some countries, this medicine may only be approved for veterinary use.
In the US, Ketoconazole (ketoconazole systemic) is a member of the drug class azole antifungals and is used to treat Blastomycosis, Chromomycosis, Chronic Mucocutaneous Candidiasis, Coccidioidomycosis, Dermatophytosis, Esophageal Candidiasis, Histoplasmosis, Onychomycosis - Fingernail, .
Asgar Rangoonwala. President Xian Janssen, China, Pharmaceutical Companies of Johnson & Johnson. Location Chaoyang District, Beijing, China IndustryTitle: President Xian Janssen, China, . Janssen Pharmaceutica was the first Western pharmaceutical company to set up a pharmaceutical factory in the People's Republic of China..
In , Paul Janssen met Ma Haide (born George Shafik Hatem), a Lebanese-American doctor who had started working in China in After three days of meetings, the two agreed to bring a modernized pharmaceutical business to China.
Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium. In , now operating as Xian-Janssen Pharmaceuticals, a new large factory was opened in the city of Xi'an, Paul Janssen – Pionier in farma en in China (in Dutch).
This company is one of China’s largest pharmaceutical joint ventures that was founded in , as a subsidiary of the Johnson & Johnson Co, a US multinational in pharmaceuticals and packaged goods that was founded in Xian-Janssen: Among foreign-invested ventures in China, Xian-Janssen Pharmaceutical, located in Xi'an is regarded as a model.
It has ranked among the top 10 joint ventures in terms of revenue since , thrice landing in the number one spot.